TCGA-CF-A1HS-01A-11R-A13Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.54927727
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.540
- HEDGEHOG_SIGNALING+0.440
- MITOTIC_SPINDLE+0.430
- MYC_TARGETS_V2+0.430
- MYC_TARGETS_V1+0.420
- TGF_BETA_SIGNALING+0.410
- TNFA_SIGNALING_VIA_NFKB+0.380
- HYPOXIA+0.310
- INFLAMMATORY_RESPONSE+0.280
Top 10 suppressed
- BILE_ACID_METABOLISM-0.380
- ADIPOGENESIS-0.270
- PEROXISOME-0.260
- OXIDATIVE_PHOSPHORYLATION-0.170
- XENOBIOTIC_METABOLISM-0.150
- FATTY_ACID_METABOLISM-0.120
- MYOGENESIS-0.110
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.090
- DNA_REPAIR-0.080
- HEME_METABOLISM-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3SO-01A-11R-A22U-07 | — | — | 0.870 |
| 2 | ERR2208969 | — | — | 0.868 |
| 3 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.859 |
| 4 | TCGA-CU-A0YN-01A-21R-A10U-07 | — | — | 0.857 |
| 5 | SRR650195 | — | — | 0.855 |
| 6 | TCGA-GC-A3RC-01A-11R-A22U-07 | — | — | 0.853 |
| 7 | TCGA-FD-A3N5-01A-11R-A21D-07 | — | — | 0.849 |
| 8 | SRR8943028 | — | — | 0.836 |
| 9 | TCGA-4Z-AA82-01A-11R-A39I-07 | — | — | 0.821 |
| 10 | SRR934963 | — | — | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |